Literature DB >> 370160

The effect of psychotomimetics on therapist--patient matching of speech "rhythms".

M Natale, C C Dahlberg, J Jaffe.   

Abstract

This study examined the effects of lysergic acid (LSD) and dextroamphetamine (DA) on therapist--patient matching of speech rhythms (mean phrase period) in psychotherapy. LSD, DA, and placebo (PL) were administered repeatedly over a 1 1/2-year period to seven patients in a randomized double-blind design. The second, fourth, and sixth encounters with LSD, DA, and PL were analyzed. These therapy dialogues were processed by an on--off detector of speech which computed probabilities of vocalizing when already talking (T), when listening (L), and when pausing (P) for therapist and patient, respectively. The mean phrase period for the therapist and the patient was calculated from the vocalization probabilities (T, P). The results show that both LSD and DA significantly enhance therapist-patient matching of mean phrase period in the earliest (second) session, an effect that disappears for both drugs, but later for DA (sixth session) than for LSD (fourth session). At no time was this effect observed in PL sessions, nor was the matching a simple function of a therapist--patient convergence of the components (T, P) of the mean phrase period.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 370160     DOI: 10.1016/0021-9924(79)90020-0

Source DB:  PubMed          Journal:  J Commun Disord        ISSN: 0021-9924            Impact factor:   2.288


  2 in total

1.  Amphetamine analogs methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) differentially affect speech.

Authors:  Gina F Marrone; Jennifer S Pardo; Robert M Krauss; Carl L Hart
Journal:  Psychopharmacology (Berl)       Date:  2009-11-17       Impact factor: 4.530

Review 2.  The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?

Authors:  Anya K Bershad; Melissa A Miller; Matthew J Baggott; Harriet de Wit
Journal:  J Psychopharmacol       Date:  2016-08-25       Impact factor: 4.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.